newsfilter
← Latest News
GlobeNewswire·

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

  • Oculis Holding AG will host an in-person & virtual R&D Day on December 8, 2026, at 10:00 EST/16:00 CET at the St. Regis New York.
  • The event will highlight clinical & strategic updates for late-stage pipeline candidates Licaminlimab & Privosegtor.
  • Nine world-renowned key opinion leaders in ophthalmology, neuro-ophthalmology, & neurology will join Oculis management to discuss the pipeline.
  • Licaminlimab updates will focus on the PREDICT-1 registrational trial for TNFR1-mediated dry eye disease, with topline results expected by year-end.
  • Privosegtor updates will cover the PIONEER program for optic neuritis, the clinical roadmap for acute multiple sclerosis relapse, & anticipated IND clearance.
  • Oculis will introduce new leadership hires Prof. Björn Tackenberg as Chief Scientific Officer & Aaron Tansy as Franchise Head, Neurology.
  • Licaminlimab is an anti-TNFα eye drop candidate using scFv technology, showing positive Phase 2 results in signs & symptoms of dry eye disease.
  • Privosegtor is a peptoid small-molecule candidate with neuroprotective potential, holding Breakthrough Therapy, PRIME, & Orphan Drug designations for optic neuritis.
  • Both Licaminlimab & Privosegtor are investigational drugs & have not received regulatory approval for commercial use in any country.
  • Live question & answer sessions will follow the formal presentations during the R&D Day.
Company
Oculis Holding AG
Keywords
Nasdaq:OCS, Oculis Holding AG, Neuro-Ophthalmology, Ophthalmology, R&D Day, Investors